Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message|
( followers)  

Analysts follow the buying trends of company insiders because, after all, no one knows more about their companies than they do. If they’re bullish enough about their companies to buy company stock, it’s probably for good reason.

We ran a screen on stocks from the biotech industry for those that have seen significant net insider buying over the last six months, indicating a somewhat longer-term trend in insider sentiment.

Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the top six stocks mentioned below. Analyst ratings sourced from Zacks Investment Research.‬


We also created a price-weighted index of the stocks mentioned below, and monitored the performance of the list relative to the S&P 500 index over the last month. To access a complete analysis of this list's recent performance, click here.



Do you think these insiders are making wise bets? Use this list as a starting-off point for your own analysis.

List sorted by net insider purchases as a percent of share float.

1. Complete Genomics, Inc. (NASDAQ:GNOM):
Develops and commercializes a DNA sequencing platform for human genome sequencing and analysis. Market cap of $194.12M. Net insider shares purchased over the last six months at 1.65M, which is 16.07% of the company's 10.27M share float. The stock is a short squeeze candidate, with a short float at 8.31% (equivalent to 8.15 days of average volume). The stock is currently stuck in a downtrend, trading 22.67% below its SMA20, 34.61% below its SMA50, and 44.69% below its SMA200. The stock has performed poorly over the last month, losing 35.21%.

2. Theravance Inc. (NASDAQ:THRX):
Engages in the discovery, development, and commercialization of small molecule medicines for various therapeutic areas, including respiratory disease, bacterial infections, and central nervous system (NYSE:CNS)/pain. Market cap of $1.71B. Net insider shares purchased over the last six months at 5.19M, which is 11.92% of the company's 43.52M share float. The stock is a short squeeze candidate, with a short float at 12.56% (equivalent to 17.6 days of average volume). The stock has gained 0.25% over the last year.

3. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP):
Focuses on the development and commercialization of in-licensed cancer drugs in North America. Market cap of $301.64M. Net insider shares purchased over the last six months at 4.34M, which is 7.57% of the company's 57.30M share float. The stock is a short squeeze candidate, with a short float at 12.96% (equivalent to 15.05 days of average volume). The stock is currently stuck in a downtrend, trading 9.72% below its SMA20, 13.74% below its SMA50, and 23.74% below its SMA200. It's been a rough couple of days for the stock, losing 5.97% over the last week.

4. Threshold Pharmaceuticals Inc. (NASDAQ:THLD):
Engages in the discovery and development of drugs targeting the microenvironment of solid tumors for patients living with cancer. Market cap of $70.65M. Net insider shares purchased over the last six months at 1.97M, which is 7.07% of the company's 27.81M share float. The stock is currently stuck in a downtrend, trading 10.31% below its SMA20, 6.54% below its SMA50, and 16.8% below its SMA200. It's been a rough couple of days for the stock, losing 13.25% over the last week.

5. MannKind Corp. (NASDAQ:MNKD):
Focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer. Market cap of $496.38M. Net insider shares purchased over the last six months at 3.48M, which is 4.39% of the company's 79.31M share float. The stock is a short squeeze candidate, with a short float at 30.96% (equivalent to 25.54 days of average volume). The stock has recently rebounded, and is currently trading 13.59% above its SMA20 and 24.85% above its SMA50. However, the stock still trades -12.22% below its SMA200. The stock has had a good month, gaining 25.5%.

6. PharmAthene, Inc. (NYSEMKT:PIP):
Engages in the development and commercialization of medical countermeasures against biological and chemical weapons in the United States. Market cap of $84.88M. Net insider shares purchased over the last six months at 430.0K, which is 1.42% of the company's 30.21M share float. The stock is a short squeeze candidate, with a short float at 9.19% (equivalent to 7.47 days of average volume). It's been a rough couple of days for the stock, losing 20% over the last week.

7. Seattle Genetics Inc. (NASDAQ:SGEN):
Focuses on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases in the United States. Market cap of $2.18B. Net insider shares purchased over the last six months at 1.48M, which is 1.30% of the company's 113.13M share float. The stock is a short squeeze candidate, with a short float at 24.49% (equivalent to 11.55 days of average volume). The stock has gained 19.22% over the last year.

8. Corcept Therapeutics Inc. (NASDAQ:CORT):
Engages in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders. Market cap of $261.02M. Net insider shares purchased over the last six months at 556.90K, which is 1.10% of the company's 50.81M share float. The stock has had a couple of great days, gaining 11.11% over the last week.

9. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN):
Develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States. Market cap of $5.33B. Net insider shares purchased over the last six months at 675.38K, which is 0.95% of the company's 71.07M share float. The stock is a short squeeze candidate, with a short float at 12.39% (equivalent to 6.91 days of average volume). It's been a rough couple of days for the stock, losing 12.07% over the last week.

10. Ligand Pharmaceuticals Inc. (NASDAQ:LGND):
Operates as a biotechnology company. Market cap of $269.09M. Net insider shares purchased over the last six months at 121.60K, which is 0.88% of the company's 13.77M share float. The stock is a short squeeze candidate, with a short float at 6% (equivalent to 6.92 days of average volume). The stock has performed poorly over the last month, losing 10.18%.

11. QLT Inc. (NASDAQ:QLTI):
Engages in the development and commercialization of therapies for the eye. Market cap of $364.62M. Net insider shares purchased over the last six months at 258.32K, which is 0.86% of the company's 30.12M share float. The stock has gained 18.28% over the last year.

12. Medivation, Inc. (NASDAQ:MDVN):
Focuses on the development of small molecule drugs for the treatment of castration-resistant prostate cancer, Alzheimer's disease, and Huntington disease. Market cap of $592.77M. Net insider shares purchased over the last six months at 87.52K, which is 0.40% of the company's 21.77M share float. The stock is a short squeeze candidate, with a short float at 7.52% (equivalent to 5.63 days of average volume). It's been a rough couple of days for the stock, losing 7.97% over the last week.

13. Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS):
Focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Market cap of $57.45M. Net insider shares purchased over the last six months at 100.0K, which is 0.38% of the company's 26.15M share float. This is a risky stock that is significantly more volatile than the overall market (beta = 2.07). The stock has performed poorly over the last month, losing 20.65%.

14. Questcor Pharmaceuticals, Inc. (QCOR):
Provides prescription drugs for central nervous system and inflammatory disorders. Market cap of $1.70B. Net insider shares purchased over the last six months at 181.88K, which is 0.33% of the company's 54.96M share float. The stock has had a couple of great days, gaining 8.39% over the last week.

15. Aastrom Biosciences, Inc. (NASDAQ:ASTM):
Engages in developing autologous cell therapies for the treatment of severe and chronic cardiovascular diseases. Market cap of $86.53M. Net insider shares purchased over the last six months at 46.92K, which is 0.12% of the company's 38.38M share float. The stock is a short squeeze candidate, with a short float at 8.76% (equivalent to 9.17 days of average volume). The stock has performed poorly over the last month, losing 13.51%.

*Insider data sourced from Yahoo! Finance, all other data sourced from Finviz.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Source: 15 Biotech Stocks Being Snapped Up By Company Insiders